07.22.2009 1:42 am
Biologics prompt exclusivity debate
St. Louis Post-Dispatch
BY ANDREW POLLACK
New York Times
A bitter congressional fight over the cost of super-expensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?
But what few people…
- Comments Off
- Email this

